Abstract
Diagnosing Alzheimer’s disease (AD) poses significant challenges to health care, often resulting in delayed or inadequate patient care. The clinical integration of blood-based biomarkers (BBMs) for AD holds promise in enabling early detection of pathology and timely intervention. However, several critical considerations, such as the lack of consistent guidelines for assessing cognition, limited understanding of BBM test characteristics, insufficient evidence on BBM performance across diverse populations, and the ethical management of test results, must be addressed for widespread clinical implementation of BBMs in the United States. The Global CEO Initiative on Alzheimer’s Disease BBM Workgroup convened to address these challenges and provide recommendations that underscore the importance of evidence-based guidelines, improved training for health-care professionals, patient empowerment through informed decision making, and the necessity of community-based studies to understand BBM performance in real-world populations. Multi-stakeholder engagement is essential to implement these recommendations and ensure credible guidance and education are accessible to all stakeholders.
If you do not see content above, kindly GO TO SOURCE.
Not all publishers encode content in a way that enables republishing at Neuro.vip.
This post is Copyright: Michelle M. Mielke,
Matthew Anderson,
J. Wesson Ashford,
Andreas Jeromin,
Pei‐Jung Lin,
Allyson Rosen,
Jamie Tyrone,
Lawren VandeVrede,
Deanna Willis,
Oskar Hansson,
Ara S. Khachaturian,
Suzanne E. Schindler,
Joan Weiss,
Richard Batrla,
Sasha Bozeat,
John R. Dwyer,
Drew Holzapfel,
Daryl Rhys Jones,
James F. Murray,
Katherine A. Partrick,
Emily Scholler,
George Vradenburg,
Dylan Young,
Joel B. Braunstein,
Samantha C. Burnham,
Fabricio Ferreira de Oliveira,
Yan Helen Hu,
Soeren Mattke,
Zul Merali,
Mark Monane,
Marwan Noel Sabbagh,
Eli Shobin,
Michael W. Weiner,
Chinedu T. Udeh‐Momoh | October 6, 2024